Proliferation of pluripotent, bone marrow stem cells, which develop to lymphoid and myeloid progenitors, is negatively regulated by estrogen. Although in estrogen deficiency and in estrogen receptor knockout mice there is significant alteration in bone marrow hematopoiesis, the effects of aging on estrogen receptor deficiencies in mice have not been investigated yet. In this study we show that by 1.5 years of age, estrogen receptor ␤ knockout (ER␤ ؊/؊ ) mice develop pronounced splenomegaly that is much more severe in females than in males. Further characterization of these mice revealed myelogenous hyperplasia in bone marrow, an increase in the number of granulocytes and B lymphocytes in blood, lymphadenopathy, and infiltration of leukocytes in the liver and lung. Analysis by flow cytometry of the bone marrow cells revealed that the percentage and total number of Gr-1 hi ͞Mac-1 hipositive granulocytes were increased by 15-30% and 100%, respectively. The numbers of B cells in the bone marrow and spleen were significantly higher in ER␤ ؊/؊ mice than in WT littermates. Some of the ER␤ ؊/؊ mice also had a severe lymphoproliferative phenotype. Thus the absence of ER␤ results in a myeloproliferative disease resembling human chronic myeloid leukemia with lymphoid blast crisis. Our results indicate a previously unknown role for ER␤ in regulating the differentiation of pluripotent hematopoietic progenitor cells and suggest that the ER␤ ؊/؊ mouse is a potential model for myeloid and lymphoid leukemia. Furthermore, we suggest that ER␤ agonists might have clinical value in the treatment of leukemia. O ver 100 years ago, it was noted that women were more affected by systemic lupus erythematosus than men. In fact, the incidence of many autoimmune diseases is higher in women (1). For this reason it has been speculated for a long time that estrogen plays important roles in the immune system. Loss of estrogen in ovariectomized mice results in splenomegaly (2) and increased production of colony-forming units-granulocyte͞ erythroid͞macrophage͞megakaryocytes, burst-forming unitserythroid cells (3-5), and B lymphocytes in mouse bone marrow (6). Conversely, pregnancy or administration of exogenous estrogen decreases bone marrow B lymphocyte population in mice (7, 8) . Recently, it was shown that estrogen represses the differentiation of multipotent hematopoietic stem cells into both lymphoid and myeloid cells (9, 10). Thus, estrogen is directly implicated in the proliferation and differentiation of various cell lineages in normal hematopoietic tissue.
O
ver 100 years ago, it was noted that women were more affected by systemic lupus erythematosus than men. In fact, the incidence of many autoimmune diseases is higher in women (1) . For this reason it has been speculated for a long time that estrogen plays important roles in the immune system. Loss of estrogen in ovariectomized mice results in splenomegaly (2) and increased production of colony-forming units-granulocyte͞ erythroid͞macrophage͞megakaryocytes, burst-forming unitserythroid cells (3) (4) (5) , and B lymphocytes in mouse bone marrow (6) . Conversely, pregnancy or administration of exogenous estrogen decreases bone marrow B lymphocyte population in mice (7, 8) . Recently, it was shown that estrogen represses the differentiation of multipotent hematopoietic stem cells into both lymphoid and myeloid cells (9, 10) . Thus, estrogen is directly implicated in the proliferation and differentiation of various cell lineages in normal hematopoietic tissue.
Estrogen exerts its effects through two distinct receptors, estrogen receptor (ER)␣ and ER␤. ER␣ has been detected in nonhematopoietic cells in bone marrow and in B lymphocyte precursors in mouse (8) . ER␤ has also been found in nonhematopoietic cells in mouse bone marrow (11) and human spleen (12) . Recently, the roles of ER in lymphopoiesis have been investigated in ER␣ mice were similar to those of WT mice, but there were fewer bone marrow B lymphocyte subpopulations (13) . Administration of estrogen to ER␣ Ϫ/Ϫ mice caused a reduction in B lymphopoiesis (13) . In contrast to the situation in estrogen deficiency, where there is splenomegaly (2) , ER␣ Ϫ/Ϫ mice showed a slightly reduced spleen weight (14) . These results seemed to indicate that negative effects of estrogen on the immune system might be mediated by ER␤.
We have examined the long-term effects of ER␤ loss on the immune and hematological systems. We found that there is pronounced splenomegaly in 1.5-year-old ER␤ Ϫ/Ϫ mice as well as myeloproliferative disease, which resembles human chronic myeloid leukemia (CML).
Materials and Methods
Mouse Strains and Housing. ER␤ Ϫ/Ϫ mice on a C57BL͞6J͞129 background were kept in the animal facility at Huddinge University Hospital (Huddinge, Sweden) under specific pathogenfree conditions and fed standard laboratory chow.
PharMingen. Single-cell suspensions were prepared from bone marrow and spleens, and 1 ϫ 10 6 cells were incubated with 10% rat serum (Sigma) for 30 min at 4°C and stained with the monoclonal antibodies described above. After a 30-min incubation on ice, cells were washed twice and resuspended in PBS with 1% paraformaldehyde. The analyses were carried out by using a FACSCalibur (Becton Dickinson) and FACSVantage (Becton Dickinson) for cell sorting.
Western Blot Analysis. Sorted cells (10 ϫ 10 6 cells) were washed in PBS buffer and homogenized in 1 ml of 0.5 M Tris⅐HCl buffer (pH 6.8) containing 0.4% SDS. Supernatant was recovered after centrifugation at 17,310 ϫ g for 10 min, and 500 l of 40% trichloroacetic acid was added. The precipitated proteins were separated by SDS͞PAGE with 10% polyacrylamide gels and transferred to poly(vinylidene difluoride) membranes. Immunoblotting was performed after blocking the membranes with 10% fat-free powdered milk in PBS containing 0.1% Nonidet P-40. The blots were incubated overnight at 4°C with rabbit IgG raised against the ligand-binding domain of human ER␤. Signals were detected by using a peroxidase-conjugated goat anti-rabbit secondary antibody and ECL Plus (Amersham Pharmacia).
Results

Aged ER␤ ؊/؊ Mice Show Pronounced Splenomegaly and Leukocyte
Infiltration in Nonhematopoietic Organs. We studied long-term effects of ER␤ deficiency using aging ER␤ Ϫ/Ϫ mice. All female and male ER␤ Ϫ/Ϫ mice by 1.5 years of age developed a profound splenomegaly (Fig. 1A) and lymphadenopathy ( Fig. 1 B and C) , although the degree of enlargement varied among mice. Spleen ( Fig. 1 D and E) and bone marrow (Fig. 1 F and G) histology in ER␤ Ϫ/Ϫ mice revealed a significant increase in the number of megakaryocytes and in total cellularity.
We kept seven female and six male ER␤ Ϫ/Ϫ mice for Ͼ1.5 years. Two of the female mice and one male ER␤ Ϫ/Ϫ mouse died with pronounced hepatosplenomegaly with leukocyte infiltration. All the age-matched WT litter mates survived and appeared normal. In nonhematopoietic organs such as liver and lung there was a significant infiltration mainly of granulocytes with some B lymphocytes ( Fig. 1 H and I) . In some ER␤ Histological analysis of various tissues including liver, kidney, and heart did not show any sign of infection (data not shown).
Hypercellularity in ER␤ ؊/؊ Mice. The cellularity of bone marrow from the femurs, tibiae ( Fig. 2A) , and spleen ( Fig. 2B) was determined by using a hematocytometer. The total cellularity was higher in ER␤ Ϫ/Ϫ mice than WT mice (Fig. 2) . As early as 1 month of age, at a time when the spleens were of normal size, the total number of WBCs was normal, and there was no leukocyte infiltration in tissues; however, there was a significant hypercellularity of bone marrow (data not shown). This finding indicates that the cause of the splenomegaly is a primary hypercellularity in the bone marrow. Table 1 ). The number of leukocytes in the peripheral blood was increased 3-to 4-fold in 1.5-year-old mice (Table 1) . Differential blood counts in most ER␤ Ϫ/Ϫ mice indicated elevated numbers of mature neutrophilic granulocytes, eosinophils, and monocytes. In none of the 1-year-old mice analyzed was there evidence of lymphoid blast crisis (data not shown). These observations demonstrate that loss of the ER␤ gene results in myeloid cell hyperplasia with an overall hematological profile very much like the clinical picture of CML.
Granulopoiesis Is Enhanced in ER␤ ؊/؊ Mice. Flow-cytometric analysis confirmed the age-dependent 15-30% increase in Gr-1 hi ͞ Mac-1 hi granulocyte population in bone marrow (Fig. 4A) and that there was a 2-fold increase in the absolute number of granulocytes in this tissue (Fig. 4B) . Although the total number of pro͞pre-B lymphocytes (B220 ϩ ͞IgM Ϫ ) in ER␤ Ϫ/Ϫ mice was higher than in WT mice (Fig. 4B) , there was a relative decrease in the percentage of B lymphocytes in bone marrow of ER␤ Ϫ/Ϫ mice because of the overall hypercellularity (Fig. 4A) . Together, these results indicate that ER␤ Ϫ/Ϫ mice develop a progressive myeloid hyperplasia with overproduction of mature granulocytes and bone marrow B cells. Because the population of B lymphocytes is smaller than that of myeloid cells in normal bone marrow, the leukocytosis is manifested as granulocytosis in peripheral blood.
Granulocytes in peripheral blood do not have potential to proliferate, but B lymphocytes have great ability to develop and proliferate in the secondary lymph organs. Because myeloid leukemia is a disease of multipotent stem cells, it is not surprising that B cell lymphoproliferative disease appears in the late stage of myeloid leukemia. In ER␤ Ϫ/Ϫ mice, the percentage of granulocytes and B lymphocytes in spleen was not different than that of WT mice (data not shown), but the total number of each cell type was increased because splenic cellularity increased by 2-to 5-fold. Only when the spleen has tripled its normal size is there a significant shift toward the leukemic disease. Examination of blood smears of ER␤ Ϫ/Ϫ mice with fully developed myeloproliferative disease, which is associated with moderately elevated numbers of leukocytes, revealed that there was granulocytosis. Morphologically, the WBCs at this disease stage appeared mostly normal. Transition of the chronic form to fatal blast crisis is a characteristic feature of human CML. Histological analysis of tissues from 2-year-old ER␤ Ϫ/Ϫ mice revealed a massive blast cell infiltration of both hematopoietic and nonhematopoietic organs such as lung, liver, and spleen. Nucleated cells (leukocytes) were counted by using 1:20 dilutions of peripheral blood in Teurk solution. Red blood cells were counted by using 1:5,000 dilutions of peripheral blood in PBS buffer. *Differential cell counts were performed by identifying at least 300 cells per May-Grü nwald Giemsa-stained peripheral blood smear.
The cells positive for chloroacetate esterase staining and myeloperoxidase immunohistostaining only appeared as focal areas in infiltrated organs, and the majority of the infiltrated cells appeared to be nontransformed cells. Human CML often shows lymphoid blast crisis and anemia. At 2 years of age, surviving ER␤ Ϫ/Ϫ mice showed various phenotypes in the spleen indicating myelofibrosis (Fig. 5 E and G) , anemia (Fig. 2F) , and even accumulation of RBCs (Fig. 5H) . The results indicate that the myeloproliferative disease with various symptoms in ER␤ Ϫ/Ϫ mice can progress to blast crisis in very old mice and thus has a natural course resembling that of human CML in which there is often lymphoid blast crisis.
ER␤ Is Expressed in Bone Marrow
Granulocytes. ER␤ has been detected in rat bone, in nonhematopoietic cells in mouse bone marrow, and in peripheral monocytes, but it has not been demonstrated in bone marrow myeloid cells. We sorted out Gr-1 hi ͞Mac-1 hi bone marrow myeloid cells by fluorescenceactivated cell sorting and measured ER␤ by Western blotting of extracts from these cells. The results clearly show that ER␤ is expressed in highly purified Gr-1 hi ͞Mac-1 hi myeloid cells (Fig. 6) . One other characteristic of estrogen deficiency is splenomegaly that is caused by enhanced B lymphopoiesis and myelopoiesis (2) . Interestingly, it has been reported that the size and cellularity of spleen is reduced significantly in 4-month-old ER␣ Ϫ/Ϫ mice (14) . We have studied the size of the spleen in 1-year-old ER␣ Ϫ/Ϫ mice and found that all ER␣ Ϫ/Ϫ mice have smaller spleens than do their WT littermates (data not shown). In the immune system, loss of ER␣ does not result in a phenotype typical of classical estrogen deficiency. Splenomegaly in ER␤ Ϫ/Ϫ mice suggests that ER␤ plays a critical role in hematopoiesis in bone marrow.
Discussion
Possible Antagonism Between ER␣ and ER␤. We also investigated hematological properties of aged ER␣ Ϫ/Ϫ mice and found no bone marrow hyperplasia; instead there is granulocytopenia in peripheral blood (unpublished data). These results suggest that ER␤ is a critical ER in the mouse bone marrow and that a balance between ER␤ and ER␣ is important in overall hematopoiesis in bone marrow. Under several circumstances, ER␤ may function as an ER␣ antagonist (16) (17) (18) .
Effect of Estrogen on Myeloid Cells. Studies of ovariectomized mice have shown that ovarian hormone deficiency promotes the expansion of a pool of bone marrow-derived progenitors that differentiate into myeloid and lymphoid cells. Normal peripheral monocytes originate from bone marrow myeloid cells, predominantly express ER␤ protein, and undergo apoptosis after estrogen exposure (19) . This finding indicates that monocytes are primarily regulated by ER␤ protein. Unraveling the mechanism through which estrogen exerts its effects on myeloid cells could provide valuable information for understanding the pathogenesis of leukemic disease, because leukemia is a disease of transformed hematopoietic progenitors. The direct effects of estrogen in leukemia and leukemic cell lines have not been well studied. The presence of an estrogen-binding site in myeloid leukemia cells, named type II ER, has been reported (20) , and ligands of this protein mediated inhibitory effects on leukemic cell proliferation (20) (21) (22) .
Estrogen significantly inhibits cell growth, via cell-cycle arrest, of the ER␣-negative human monoblastic leukemia cell line U937 (23) . It is therefore interesting that normal human monocytes express ER␤ and that certain flavonoids, which are ligands of ER␤, inhibit leukemic cell growth (22, 23) . Furthermore, androgens have similar effects as estrogens on bone marrow (24); they also inhibit cell growth of the U937 cell line (23) and improve long-term survival in acute myeloid leukemia in humans (25) .
Comparison of the ER␤ ؊/؊ Phenotype with Other Mouse Models of CML. The disease we describe in ER␤ Ϫ/Ϫ mice resembles CML, is polyclonal, and seems to originate from multipotent stem cells that can differentiate into both myeloid and B lymphoid lineages. Very similarly, in two different mouse models of CML, it has been demonstrated that the cells that initiate CML-like leukemia are early multipotent progenitors. Two typical chromosomal translocations are implicated in human CML, the t(9:22) Philadelphia chromosome and t(9:12) (26). As a result of chromosome translocations, two fusion proteins, BCR-ABL and Tel-Abl tyrosine kinase, are generated. Retroviral transduction of the BCR-ABL or TEL-ABL gene into mouse bone marrow cells directly induces CML-like myeloproliferative disease (26, 27) . These murine CML-like diseases induced by human protein Tel-Abl or Bcr-Abl are characterized by massive polyclonal expansion of maturing myeloid cells, principally neutrophils. Although neutrophils constitute the predominant hematopoietic lineage in murine CML-like disease, the same spectrum of proviral clones was detected in macrophages, erythroid progenitors, and B lymphocytes (26, 27) . In mice specifically lacking JunB in the myeloid lineage (28) and in mice in which the IFN consensus sequence-binding protein has been inactivated (29) , the resulting CML-like syndrome is very similar to what we have described in ER␤ Ϫ/Ϫ mice. CML is a myeloproliferative disorder resulting from the neoplastic transformation of hematopoietic stem cells (30) . It accounts for 15-20% of all human leukemias, and many patients of CML progress to acute myeloid leukemia, which accounts for Ͼ80% of all adult acute leukemias. The disease usually has a biphasic course. The initial, chronic phase is characterized by increased proliferation and maturation of myeloid cells, with granulocytes predominating. After 3-5 years the disease progresses to a blast crisis stage, characterized by accelerated accumulation of immature myeloid or lymphoid cells. Unfortunately, present clinical interventions rarely cure CML. Elucidation of the molecular mechanisms and the genes responsible for CML is critical for developing improved therapies for the disease.
Our results suggest a previously unknown role of ER␤ in regulating the proliferation and differentiation of pluripotent hematopoietic progenitor cells. This study indicates that mutations in the ER␤ gene may be responsible for myeloproliferative disease and constitute a genetic risk factor for developing acute myeloid leukemia. ER␤ Ϫ/Ϫ mice may be a potential model for myeloid leukemia. Furthermore, it is possible that agonists against ER␤ may have a value in chemotherapy of CML including Philadelphia chromosome disease.
